Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 5/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066555 | 0.87 | KDM4E (0.41) | ALDH1A1KDM4EHPGDITGB3ITGAV | |
| SCHEMBL3867138 | 0.87 | KDM4E (0.39) | ALDH1A1KDM4EHPGDITGB3ITGAV | |
| SCHEMBL7393329 | 0.85 | KDM4E (0.36) | ALDH1A1KDM4EHPGDITGB3ITGAV | |
| SCHEMBL1069614 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDCNR2PDE4A | |
| SCHEMBL1070403 | 0.84 | ITGB3 (0.49) | ITGB3ITGAV | |
| SCHEMBL1070621 | 0.83 | ITGB3 (0.50) | ITGB3ITGAV | |
| SCHEMBL1071032 | 0.82 | ITGB3 (0.49) | ITGB3ITGAV | |
| SCHEMBL1069612 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDCNR2PDE4A | |
| SCHEMBL1070971 | 0.81 | ITGAV (0.50) | ITGB3ITGAV | |
| SCHEMBL27579682 | 0.81 | ITGB3 (0.39) | ALDH1A1KDM4EHPGDITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | claimed |
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | claimed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | claimed |
| CN-1541115-A | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | ����˹�ж�-����˹˹����ҩƷ��˾ | 2004-10-27 | — | — | CN | claimed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | claimed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | claimed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | claimed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | claimed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | claimed |
| CN-1356913-A | vitronectin receptor antagonist drugs | DU PONT PHARM CO (US) | 2002-07-03 | — | — | CN | claimed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | claimed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | claimed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-2269659-A1 | Integrin targeted imaging agents | Barnes Jewish Hospital (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | ALDH1A1 4053/4885KDM4E 4872/4885HPGD 3033/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | ALDH1A1 2648/4885KDM4E 4799/4885HPGD 1448/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | ALDH1A1 2844/4885KDM4E 4790/4885HPGD 1637/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | ALDH1A1 2648/4885KDM4E 4799/4885HPGD 1448/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | ALDH1A1 2844/4885KDM4E 4790/4885HPGD 1637/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | ALDH1A1 2844/4885KDM4E 4790/4885HPGD 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.